Use of Azathioprine and the Risk of Cancer in Inflammatory Bowel Disease

Author： Pasternak Björn   Svanström Henrik   Schmiegelow Kjeld   Jess Tine   Hviid Anders  

Publisher： Oxford University Press

ISSN： 1476-6256

Source： American Journal of Epidemiology, Vol.177, Iss.11, 2013-06, pp. : 1296-1305

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Azathioprine in inflammatory bowel disease, a safe alternative?

By Tanis A. A.  

Mediators of Inflammation, Vol. 7, Iss. 3, 1998-06 ,pp. : 141-144

Informa Healthcare

Access to resources Recommend Favorite

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 689-690

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial: weighing the global risk of cancer with thiopurines in inflammatory bowel disease—Authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 690-691

John Wiley & Sons Inc

Access to resources Recommend Favorite

Treatment with infliximab or azathioprine negatively impact the efficacy of hepatitis B vaccine in inflammatory bowel disease patients

By  

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol. 30, Iss. 11, 2015-11 ,pp. : 1591-1595

John Wiley & Sons Inc

Access to resources Recommend Favorite

HLA‐DQA1‐HLA‐DRB1 polymorphism is a major predictor of azathioprine‐induced pancreatitis in patients with inflammatory bowel disease

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 5, 2018-03 ,pp. : 615-620

John Wiley & Sons Inc

Access to resources Recommend Favorite